NCT07285460

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2025-12-18Est. Completion: 2029-08-04

Enrollment target: 85 participants

Locations

The Luskin Orthopaedic Institute for Children- Site Number : 8400013, Los Angeles, California, United States
Children's Hospital Los Angeles- Site Number : 8400002, Los Angeles, California, United States
The Center for Inherited Blood Disorders- Site Number : 8400009, Orange, California, United States
UCLA Medical Center - Harbor- Site Number : 8400011, Torrance, California, United States
University of Michigan Health System - Ann Arbor- Site Number : 8400003, Ann Arbor, Michigan, United States
Cure 4 The Kids Foundation- Site Number : 8400001, Las Vegas, Nevada, United States
Hackensack Meridian Health - Hackensack University Medical Center- Site Number : 8400008, Hackensack, New Jersey, United States
University of Texas - Southwestern Medical Center- Site Number : 8400015, Dallas, Texas, United States
Investigational Site Number : 0560002, Brussels, Belgium
Investigational Site Number : 0560001, Brussels, Belgium
Universidade Estadual de Campinas (UNICAMP)- Site Number : 0760001, Campinas, São Paulo, Brazil
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760003, Ribeirão Preto, São Paulo, Brazil

Hemophilia A and B

Hemophilia is an inherited bleeding disorder characterized by recurrent musculoskeletal bleeding, particularly into join…

Istanbul, Turkey (Türkiye)Completed Sep 15, 2026

Hemophilia A or B

This is a real-world, mixed-methods observational study conducted among adolescent (ages 12-17 years) and adult particip…

Indianapolis, United StatesEst. completion Mar 2, 2029

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.